WO1998019327A1 - Luminaire utilise a des fins therapeutiques - Google Patents

Luminaire utilise a des fins therapeutiques Download PDF

Info

Publication number
WO1998019327A1
WO1998019327A1 PCT/EP1996/005845 EP9605845W WO9819327A1 WO 1998019327 A1 WO1998019327 A1 WO 1998019327A1 EP 9605845 W EP9605845 W EP 9605845W WO 9819327 A1 WO9819327 A1 WO 9819327A1
Authority
WO
WIPO (PCT)
Prior art keywords
illuminant according
illuminant
light
fibrinogen
lamp
Prior art date
Application number
PCT/EP1996/005845
Other languages
German (de)
English (en)
Inventor
Gosbert Weth
Original Assignee
Gosbert Weth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gosbert Weth filed Critical Gosbert Weth
Priority to EP96944071A priority Critical patent/EP0912989A1/fr
Publication of WO1998019327A1 publication Critical patent/WO1998019327A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J61/00—Gas-discharge or vapour-discharge lamps
    • H01J61/02—Details
    • H01J61/12—Selection of substances for gas fillings; Specified operating pressure or temperature
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J61/00—Gas-discharge or vapour-discharge lamps
    • H01J61/02—Details
    • H01J61/38—Devices for influencing the colour or wavelength of the light
    • H01J61/42—Devices for influencing the colour or wavelength of the light by transforming the wavelength of the light by luminescence
    • H01J61/44—Devices characterised by the luminescent material

Definitions

  • the invention relates to a lamp for therapeutic purposes and / or lighting purposes.
  • the invention has for its object to design a lamp of the type mentioned so that side effects occurring when using the lamp are at least reduced.
  • this object is achieved by an illuminant for therapeutic purposes which emits light which has the following spectral lines: 251 nm ( ⁇ 5 nm), 265 nm
  • spectral lines which, as the bandwidth specifications make clear, do not necessarily have to be extremely narrow-band lines, correspond to the absorption lines of the body's own vital substances, which are also present in plants and which are used as a phosphor in the illuminant according to the invention.
  • the light spectrum of the illuminant according to the invention thus differs fundamentally from the light spectrum of the previous daylight lamps and comes very close to sunlight, so that the illuminant according to the invention could also be referred to as a sunlight lamp. It can be used both as a table lamp and as a ceiling lamp to prevent diseases and to increase well-being and performance. If the illuminant according to the invention is used as workplace lighting, because of the sunlight spectrum, such high light densities (lux) are not required at the workplace, since the workplace is better illuminated.
  • lux high light densities
  • the light of the illuminant according to the invention contains a UV component (UV-A and / or UV-B) without which it would not be able to produce the desired effects.
  • the illuminant according to the invention can be used in schools, hospitals, in particular in intensive care units, in prisons and also kindergartens. As has been shown when used in hospitals, the well-being of both patients and staff improves.
  • the illuminant emits light which also has at least one spectral line from the following group has: 380 nm ( ⁇ 15 nm), 410 nm ( ⁇ 15 nm), 438 nm ( ⁇ 15 nm), 490 nm ( ⁇ 15 nm), 515 nm ( ⁇ 15 nm) 540 nm ( ⁇ 15 nm), 580 nm ( ⁇ 15 nm), 610 nm ( ⁇ 15 nm), 650 nm ( ⁇ 15 nm), 690 nm ( ⁇ 15 nm), 710 nm ( ⁇ 15 nm), 740 nm ( ⁇ 15 nm), 770 nm ( ⁇ 15 nm), 800 nm
  • spectral lines also correspond to the absorption lines of the body's own vital substances which, incidentally, are also present in plants and serve as luminescent material in the illuminant according to the invention.
  • the lamp according to the invention could in principle also be constructed like an incandescent lamp, according to a preferred embodiment of the invention the lamp is designed as a fluorescent tube, in particular like an energy-saving lamp.
  • the lamp according to the invention is designed as an energy-saving lamp, there is a considerable saving effect because of the high energy costs of conventional lamps.
  • the lamp according to the invention can be screwed into any conventional lamp holder.
  • the lamp according to the invention is designed as an energy-saving lamp, considerable space savings can be achieved if it has a tubular discharge space which is folded.
  • the fluorescent tube contains helium and / or xenon and / or at least one ' chlorinated hydrocarbon as carrier gas; as a phosphor at least one halogenated hydrocarbon.
  • the illuminant according to the invention can have a shield which is formed from a material which contains quartz and / or silicon dioxide. Contains crystals that almost completely eliminate the electrical fields, shield them.
  • the illuminant according to the invention is operated with direct current or alternating current with a frequency of at least 1 kHz, the light from the illuminant is at least largely flicker-free and is again felt to be considerably more pleasant than that of conventional lamps.
  • the illuminant according to the invention Due to the novel light spectrum of the illuminant according to the invention, which is much more pleasant for the eye than the conventional illuminant, a smaller number of illuminants is required for a given lighting task, for example only 2/3 of the number of illuminants that would be required if commercially available illuminants were used .
  • the illuminant according to the invention therefore also gives a clear saving effect, which can be of the order of 70%.
  • the use of the illuminant according to the invention influences the fibrinogen level, arteriosclerosis, immunological diseases, psychoses, depression and other diseases, e.g. Avoiding heart attacks and strokes, as well as strengthening the immune system and slowing the aging process.
  • the use of the illuminant according to the invention resulted in a reduction in the embolisms and thromboses occurring only when the fibrinogen was increased to less than 0.1%.
  • the death rate dropped significantly, namely by over 60%.
  • the high death rates in the clinics and at home are caused by embolisms, thromboses, acute heart attacks and strokes. Almost all patients are responsible for disorders of the coagulation system. It is known that the high death rate in winter is caused by the increase in fibrinogen will, as reported in Lancet magazine.
  • the use of the illuminant according to the invention lowers the fibrinogen level to normal values and thus prevents the diseases caused by the coagulation disorder (increase in fibrinogen).
  • Fibrinogen is a separate risk factor for heart attack and stroke. Sticking together (aggregating) the blood closes important blood vessels, which can lead to death.
  • FIG. 1 shows the result of an examination carried out on 1120 patients.
  • the fibrinogen drops significantly, as shown in FIG. 1.
  • 1 shows the relationships for patients with CHK (coronary heart disease).
  • the fibrinogen value was 543 mg / dl, for example, before treatment with the illuminant according to the invention and after a treatment period of 4 weeks with twice daily half an hour of irradiation with the illuminant according to the invention 389 mg / dl.
  • pathological proteins are formed here.
  • the formation of these proteins is prevented and the disease is thereby improved.
  • Skin rashes e.g. psoriasis, neurodermatitis
  • psoriasis e.g. psoriasis, neurodermatitis
  • the use of the illuminant according to the invention results in a significant clinical improvement (e.g. increase in fibrinogen, lower arteriosclerosis ). It is important that the effect can only be achieved through the eyes. Whole body radiation as in the previously known therapies is therefore advantageously no longer necessary even for the treatment of skin diseases.
  • Illuminant the effect achieved without side effects if the procedure is used correctly.
  • One of the most important detection parameters are the immunological measurements. Starting with the lowering of the blood up to the sensitive CRP (C-reactive protein) and with the electrophoresis. The tumor necrosis factors, the interleukins, the prostaglandins etc. are also influenced. All of these parameters are positively influenced by the light of the illuminant according to the invention.
  • the illuminant according to the invention can, as already mentioned, also be used prophylactically, for example by is used as a table or ceiling lamp.
  • the negative effects of the light emitted by monitors and televisions, for example, on the organism can be reduced or even eliminated by adding the illuminant according to the invention.
  • the observed signs of fatigue no longer occur.
  • This can either be achieved in that the lamp is designed as a picture tube.
  • the illuminant according to the invention in To install the housing of a device containing a picture tube or to design it as a screen attachment for such a device, in such a way that when the image displayed by means of the picture tube is viewed, the light of the light-emitting means according to the invention falls into the eyes of the viewer.
  • the illuminant according to the invention can be used as a kind of lighting, for example as a ceiling or table lamp, in rooms in which devices containing picture tubes are used. eg monitors or televisions can be used.
  • the illuminant according to the invention can be used, so to speak, as a work device that promotes work quality and quantity.
  • the fibrinogen metabolism plays a central role in the metabolism.
  • Fibrinogen is a cardiovascular factor, especially at night or in winter.
  • the fibrinogen values in winter were also increased by more than 30% in connection with the use of the subject and patient examined according to the invention (over 1000 people). After treatment with the luminous In the mean, none of the subjects and patients had a heart attack or stroke, although the fibrinogen levels in these patients were also increased before the therapy.
  • Fibrinogen appears to be a multipotent component of arteriogenesis, which plays an important role in almost all stages of arteriosclerosis. Fibrinogen and microthrombus deposition on a normal intima is associated with destruction of the endothelium and intimaedema, which in turn is a closer characteristic of an earlier proliferative lesion. Fibrin deposits on or in the intima promote migration or proliferation of the smooth muscle cells and contribute to the growth of the plaques. Fibrin is also a continuous source of FDPs that maintain mitogenic activity and proliferation in smooth muscle cells in growing plaques and are chemo-attractive to blood leukocytes. The deposition of lipid in fibrous plaques should also be influenced by the fibrin, which binds lipoprotein A with high affinity and thus immobilizes it in the lesion.
  • the invention can bring significant progress here, since the use of the illuminant according to the invention leads to a biochemical change in the organism: fibrinogen, the most important cardiovascular risk factor, is reduced to such an extent by the use of the illuminant according to the invention that there is no risk of arteriosclerosis.
  • the acute heart attack or stroke is characterized by the fact that the fibrinogen level rises extremely.
  • Framingham study it could be shown that a heart attack or stroke occurs almost exclusively with an increase in fibrinogen. This leads to an aggregation of the blood and occlusion of blood vessels, which are responsible for the heart attack or stroke.
  • the increased fibrinogen level is the cause of cardiovascular diseases (the most common diseases). Cerebral diseases such as apoplexy are the third leading cause of death.
  • the increase in fibrinogen level is responsible for the damage to the blood vessel system and thus for this cause of death. It does not have to be an arterioscler rose present. Even if the blood vessels are not severely damaged, there is an acute occlusion of the vessels. This can be prevented by therapy with the illuminant according to the invention.
  • the use of the illuminant according to the invention increases the dopamine level, i.e. vigilance increases. This also improves sleep quality. Melatonin levels also rise. In addition, pronounced fluctuations in sugar are eliminated; insulin can be saved in diabetics.
  • the use of the illuminant according to the invention significantly improves osteoporosis, which is a problem in old age. Many of the patients affected suffer fractures from osteoporosis, become immobile or have pain from osteopenia and osteoporosis.
  • the use of the illuminant according to the invention stimulates the formation of vitamin D. Calcium storage in the bones is increased, thus reducing osteoporosis. The pain is gradually eliminated.
  • the HDL (high-density lipoprotein) metabolism apart from an increase, is hardly influenced in some cases.
  • the LDL (Low Density Lipoprotein) concentration is significantly reduced, by about 30%. As a result, the cholesterol level drops.
  • depression Light and depression are closely related. The investigations in connection with the use of the illuminant according to the invention thus showed that use of the illuminant according to the invention for half an hour led to a significant improvement in the findings. Well-being increased. The values on the Hamilton Depression Scale have improved.
  • the light therapy - in the following light therapy should be understood that the respective person or the respective group of people is exposed to the light of the illuminant according to the invention, be it when using the illuminant according to the invention as a therapy device or as a "normal" lighting fixture - was combined with the drug Hypericin Without light therapy, hypericin had significantly less effect than shown in Figures 2 and 3.
  • the value on the Hamilton Depression Scale fell to 18 instead of 12 after 2 weeks and to 15 instead of 10 after 4 weeks
  • the blood sedimentation rate BSG also a parameter for inflammation, also decreases, as can be seen from FIG. 5.
  • the ADL (Activity of Daily Life) status is significantly increased by the use of the illuminant according to the invention. 6 and 7, an increase in the ADL value from 59 to 92 was found after the light therapy. This is a highly significant result. Without the use of the illuminant according to the invention, only an increase in the ADL status to 82 is achieved. Incidentally, the maximum value of the ADL status is 100 and stands for the fact that a person is fully able to cope with the activities of daily life independently.
  • the use of the illuminant according to the invention leads to a lowering of the interleukin 6, which is increased in AIDS patients. Interferon is increased.
  • the use of the illuminant according to the invention stimulates the pituitary hormones FSH (increase of 16% and LH (24% increase); there is also an inhibition of appetite.
  • Pathological amino acids e.g. homocysteine
  • the use of the illuminant according to the invention prevents the formation of pathological amino acids. Homocysteine drops by 30% with pathologically elevated values.
  • N- (aminoacyl) amino acids and / or also N- (ercaptoacyl-) amino acids and / or hypericin (extract of St. John's wort)
  • This antiviral effect could not be achieved either by using the illuminant according to the invention alone, or by the N- (aminoacyl) amino acids and / or also N- (mercaptoacyl-) amino acids and / or hypericin (extract of St. John's wort).
  • This effect is improved by taking blood from the vein and mixing it with the substances mentioned above. By passing the blood past the illuminant according to the invention, the virus is destroyed. The hepatitis viruses were destroyed to over 98% and in the case of AIDS viruses (retroviruses) to 99% by multiple
  • FIG. 14 is a rough schematic representation of a conventional picture tube and a lamp according to the invention. holding device also in a schematic representation, and
  • Fig. 15 in a rough schematic representation of an inventive lamp designed as a picture tube in a schematic representation.
  • FIG. 10 shows an illuminant according to the invention, which is designed as a fluorescent tube and is designed with a double chamber and emits a light containing the spectral lines mentioned at the outset, which is similar to the sunlight spectrum and also has a proportion of certain UV-A and UV-B light components.
  • the tubular chamber 1 which is formed from glass and is enclosed by glass, has two partial chambers 2 and 3 which are hermetically separated from one another by a wall. These are each connected to an alternating current supply 4 or 5, which emits a supply current of a frequency of at least 1 kHz, preferably 60 kHz, during operation of the fluorescent tube.
  • One sub-chamber 2 is filled with xenon and neon as the carrier gas and is coated on its walls with halogenated hydrocarbons which serve as the luminescent material.
  • the other sub-chamber 3 is filled with neon and / or chlorinated hydrocarbons as the carrier gas and is also coated on its walls with halogenated hydrocarbons serving as a phosphor.
  • 10 therefore emits light with UV-A and UV-B light components, which contains the spectral lines mentioned at the outset, the light emerging from the sub-chamber 2 having a different spectral composition than the light emerging from the sub-chamber 3.
  • 10 is the operation with high-frequency alternating currents (eg approx. 30,000 Hz, not 50 Hz). Operation with direct currents is also possible. While conventional fluorescent lamps often run with electrons when operated with direct currents, this is excluded by the two-chamber system if the chambers are polarized differently, so that there is an exchange of electrons, which prevents electron depletion in a chamber .
  • FIG. 11 A further embodiment of an illuminant according to the invention designed as a fluorescent tube is shown in FIG. 11.
  • This fluorescent tube can therefore also be operated with direct current or high-frequency alternating current.
  • the chamber 7 accommodated in the tubular piston 6 is filled with inert gas, e.g. Neon and / or xenon and chlorinated hydrocarbons filled as carrier gas and coated on their walls with halogenated hydrocarbons serving as phosphors.
  • inert gas e.g. Neon and / or xenon and chlorinated hydrocarbons filled as carrier gas and coated on their walls with halogenated hydrocarbons serving as phosphors.
  • UV-A and UV-B light components which contains the spectral lines mentioned at the beginning.
  • the chamber 7 contains a metal wire 8 for conducting the ion current.
  • 10 and 11 there are preferably ring-shaped shields 9 and 10 or 11 and 12 made of quartz and / or crystal which serve to prevent harmful electromagnetic radiation, so-called electrosmoke, at the ends of the lamps.
  • This further increases the therapeutic effectiveness of the illuminant according to the invention.
  • 12 and 13 show so-called energy-saving lamps with tubular, U-shaped pistons 13 and 14, respectively, according to the invention, which otherwise correspond in their construction to the inventive lamps according to FIGS. 10 and 11, ie the energy-saving lamp according to FIG. 12 is double-chambered and that according to FIG. 13 is single-chambered.
  • the light Compared to the conventional illuminant, the light largely corresponds to sunlight. Different carrier gases also enable the broad light spectrum, which achieves a full-spectrum effect which is important for the eye and which is also important for the clinical effect.
  • the illuminants according to FIGS. 10 and 13 emit a light that is largely continuous compared to the conventional illuminant.
  • the illuminants according to the invention can be used, for example, in a rainbow 14 shows a device 22 containing a conventional picture tube 21, for example a television or a monitor, which has a housing which, in addition to the picture tube and the electronics required for operating the device, contains a lamp 23 according to the invention which, for example, according to FIG 10 to 13 is constructed.
  • a lamp 23 according to the invention which, for example, according to FIG 10 to 13 is constructed.
  • FIG. 15 shows an illuminant according to the invention designed as a picture tube 24, the screen of which is coated, at least among others, with such phosphors that the light coming from the picture tube contains the spectral lines mentioned at the beginning.
  • the harmful disadvantages which arise from the light of conventional picture tubes are avoided since the light emitted by the picture tube 24 according to the invention corresponds to natural sunlight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Social Psychology (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne un luminaire utilisé à des fins thérapeutiques et/ou d'éclairage, qui fournit de la lumière présentant les lignes spectrales suivantes: 251 nm (+/-15 nm), 290 nm (+/-15 nm), 319 nm (+/-10 nm), 335 nm (+/-15 nm), 368 nm (+/-15 nm).
PCT/EP1996/005845 1996-10-26 1996-12-27 Luminaire utilise a des fins therapeutiques WO1998019327A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96944071A EP0912989A1 (fr) 1996-10-26 1996-12-27 Luminaire utilise a des fins therapeutiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996144525 DE19644525A1 (de) 1996-10-26 1996-10-26 Energiesparlampe für medizinische Therapien
DE19644525.6 1996-10-26

Publications (1)

Publication Number Publication Date
WO1998019327A1 true WO1998019327A1 (fr) 1998-05-07

Family

ID=7810059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005845 WO1998019327A1 (fr) 1996-10-26 1996-12-27 Luminaire utilise a des fins therapeutiques

Country Status (3)

Country Link
EP (1) EP0912989A1 (fr)
DE (1) DE19644525A1 (fr)
WO (1) WO1998019327A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003036593A2 (fr) * 2001-10-24 2003-05-01 Elpida Tzouriadou-Teske Procede et systeme pour transformer une chambre ordinaire en un environnement benefique
DE102004061499A1 (de) * 2004-12-15 2006-06-29 Weth, Gosbert, Dr. med. Dr. rer. nat. Therapeutisch wirksame Lampe und Verwendung einer solchen Lampe

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007143862A1 (fr) * 2006-06-16 2007-12-21 Medela Holding Ag Appareil et procédé pour prévenir et traiter une carence en vitamine d chez un nouveau-né

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718735A1 (de) * 1977-04-27 1978-11-02 Patra Patent Treuhand Quecksilberdampfhochdruckentladung
US4370595A (en) * 1979-07-03 1983-01-25 U.S. Philips Corporation Low-pressure mercury vapor discharge lamp
EP0606897A2 (fr) * 1993-01-14 1994-07-20 Imab-Stiftung Filtre pour rayonnement Ultraviolet

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718735A1 (de) * 1977-04-27 1978-11-02 Patra Patent Treuhand Quecksilberdampfhochdruckentladung
US4370595A (en) * 1979-07-03 1983-01-25 U.S. Philips Corporation Low-pressure mercury vapor discharge lamp
EP0606897A2 (fr) * 1993-01-14 1994-07-20 Imab-Stiftung Filtre pour rayonnement Ultraviolet

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003036593A2 (fr) * 2001-10-24 2003-05-01 Elpida Tzouriadou-Teske Procede et systeme pour transformer une chambre ordinaire en un environnement benefique
WO2003036593A3 (fr) * 2001-10-24 2003-12-11 Elpida Tzouriadou-Teske Procede et systeme pour transformer une chambre ordinaire en un environnement benefique
US7425197B2 (en) 2001-10-24 2008-09-16 Elpida Tzouriadou-Teske Method and a system for transforming a common room into a healing environment
DE102004061499A1 (de) * 2004-12-15 2006-06-29 Weth, Gosbert, Dr. med. Dr. rer. nat. Therapeutisch wirksame Lampe und Verwendung einer solchen Lampe

Also Published As

Publication number Publication date
DE19644525A1 (de) 1998-05-07
EP0912989A1 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
EP0198212B1 (fr) Dispositif pour l'irradiation optique de sang veineux autocorporel efficace physiologiquement et thérapeutiquement
EP0097193B1 (fr) Appareil a rayonnement ultra-violet pour la photo therapie de dermatoses et notamment de psoriasis
DE60120430T2 (de) Verfahren zur steuerung der wachsamkeit einer person
DE202009018852U1 (de) Anzeigesystem mit circadianer Wirkung auf den Menschen
DE3032741A1 (de) Hautbraeunungs-fluoreszenzlampe mit einer phosphoren-kombination
DE2718735A1 (de) Quecksilberdampfhochdruckentladung
EP2260505B1 (fr) Lampe à décharge à basse pression pour influencer la production de mélatonine propre au corps
DE2105925C3 (de) Arzneimittel mit kalkspiegelanhebender und recalcifikationsfördernder Wirkung
WO1998019327A1 (fr) Luminaire utilise a des fins therapeutiques
Birkmayer et al. Störung des Tyrosin-und Tryptophanmetabolismus bei Depression
Tsuchida et al. Brain Tumors in tuberous sclerosis: report of 4 cases
DE102015104360A1 (de) Pharmazeutische zusammensetzung vom inhalationstyp für die behandlung einer herzkrankheit und zubereitungsverfahren dafür
DE2028781A1 (de) Hochdruck-Quecksilberdampf Jodid-Entladungslampe
DE102015104358A1 (de) Pharmazeutische zusammensetzung vom inhalationstyp für die behandlung der parkinson-krankheit und zubereitungsverfahren dafür
DE19549092A1 (de) Lichttherapie mit der Biolampe zur Beeinflussung des Fibrinogenspiegels, der Ateriosklerose, von immunologischen Erkrankungen, der Psychose, Depression und weiteren Erkrankungen
EP0228737A2 (fr) Lampe UVA à décharge à vapeur de mercure à basse pression pour le bronzage
DE3935855A1 (de) Verwendung von dextransulfat, ggf. in kombination mit anti-androgenen mitteln zur behandlung des humanen prostatakarzinoms
DE2707894C2 (fr)
DE757286C (de) Bestrahlungsanordnung zur Erzeugung von Braeunung ohne Roetung
DE102008049476A1 (de) Hochdruckentladungslampe
DE3024691A1 (de) Elektrische entladungslampe fuer bestrahlungszwecke
WO2001021728A1 (fr) Film de substance luminescente
Steiner et al. Endoskopische Therapie von Krebsfrühstadien im Larynx—vorläufige Ergebnisse
EP0427917A2 (fr) Lampe d'irradiation pour augmenter le niveau de vitamin D3 d'une personne
DE1764685C3 (de) Elektrische Allzweck-Entladungslampe

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN JP KR US AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWW Wipo information: withdrawn in national office

Ref document number: 1996944071

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1996944071

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996944071

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998519953

Format of ref document f/p: F